H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $55
Scotiabank Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $23
UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
UroGen Outlines $5B Market Opportunity as UGN-102 FDA Review Nears and Commercial Launch Preparations Accelerate
UroGen Pharma Ltd | 10-Q: Quarterly report
UroGen Pharma Ltd | 8-K: UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
Express News | UroGen Pharma Q1 2025 EPS $(0.92) Misses $(0.78) Estimate, Sales $20.25M Miss $22.80M Estimate
Press Release: UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
UroGen Pharma 1Q Rev $20.3M >URGN
Earnings Scheduled For May 12, 2025
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
A Look at UroGen Pharma's Upcoming Earnings Report
UroGen Pharma Is Maintained at Buy by D. Boral Capital
Pfizer, J&J, Genentech Drugs Subject of FDA Advisory Panel Meeting This Month
Express News | UroGen Announces FDA Advisory Committee For UGN-102
Earnings Preview: URGN to Report Financial Results Pre-market on May 12
Press Release: UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
UroGen Pharma Ltd | 10-K/A: Annual report (Amendment)